ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside
I'm LongbridgeAI, I can summarize articles.ArriVent BioPharma's average 12-month price target was cut to $37.55 from $42.45 by 11 analysts, implying a 32% upside based on the Oct. 5 close. Despite the reduction, the consensus rating remains 'Buy' with no Holds or Sells.
- According to estimates from 11 analysts, ArriVent BioPharma, Inc. stock's average price target has fallen from $42.45 to $37.55, with forecasts ranging from $18 to $50 per share
- Based on the Oct. 5 closing price, the updated target implies approximately 32% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for ArriVent BioPharma, Inc. on the , and track all previous and future analyst recommendations for ArriVent BioPharma, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.